Abstract
Transmissible spongiform encephalopathies (TSEs), also called prion diseases, are fatal, infectious, genetic or sporadic neurodegenerative disorders of humans and animals. In humans, TSEs are represented by Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, Fatal Familial Insomnia and Kuru. In animals, the most prominent prion diseases are scrapie of sheep and goats, bovine spongiform encephalopathy (BSE) of cattle and chronic wasting disease (CWD) of deer and elk. A critical event in prion diseases is the accumulation in the central nervous system (CNS) of the abnormally folded PrPSc protein that is the protease-resistant isoform of a normal cellular protein encoded by the host and called PrPC. PrPSc (also known as rPrPSc or PrP27-30) represents the main marker of prion diseases and is routinely used in the reference method for the diagnosis of prion diseases. Most of the therapeutic strategies developed so far aimed at identifying compounds that diminish the levels of PrPSc, with variable success when tested in vivo. In this review, we present an alternative approach in which small molecules that induce PrPSc oligomers are identified. By using virtual and cellular screenings, we found several thienyl pyrimidine compounds that trigger PrPSc oligomerization and trap prion infectivity.
Keywords: Diagnosis, drug screening, oligomerization, oligomers, prion diseases, therapeutic, thienyl pyrimidine.
Current Topics in Medicinal Chemistry
Title:Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions
Volume: 13 Issue: 19
Author(s): Thibaut Imberdis, Adeline Ayrolles-Torro, Jean-Michel Verdier and Véronique Perrier
Affiliation:
Keywords: Diagnosis, drug screening, oligomerization, oligomers, prion diseases, therapeutic, thienyl pyrimidine.
Abstract: Transmissible spongiform encephalopathies (TSEs), also called prion diseases, are fatal, infectious, genetic or sporadic neurodegenerative disorders of humans and animals. In humans, TSEs are represented by Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, Fatal Familial Insomnia and Kuru. In animals, the most prominent prion diseases are scrapie of sheep and goats, bovine spongiform encephalopathy (BSE) of cattle and chronic wasting disease (CWD) of deer and elk. A critical event in prion diseases is the accumulation in the central nervous system (CNS) of the abnormally folded PrPSc protein that is the protease-resistant isoform of a normal cellular protein encoded by the host and called PrPC. PrPSc (also known as rPrPSc or PrP27-30) represents the main marker of prion diseases and is routinely used in the reference method for the diagnosis of prion diseases. Most of the therapeutic strategies developed so far aimed at identifying compounds that diminish the levels of PrPSc, with variable success when tested in vivo. In this review, we present an alternative approach in which small molecules that induce PrPSc oligomers are identified. By using virtual and cellular screenings, we found several thienyl pyrimidine compounds that trigger PrPSc oligomerization and trap prion infectivity.
Export Options
About this article
Cite this article as:
Imberdis Thibaut, Ayrolles-Torro Adeline, Verdier Jean-Michel and Perrier Véronique, Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions, Current Topics in Medicinal Chemistry 2013; 13 (19) . https://dx.doi.org/10.2174/15680266113136660174
DOI https://dx.doi.org/10.2174/15680266113136660174 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Meet Our Associate Editor:
Current Alzheimer Research The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design Editorial [Hot Topic: Frontotemporal Lobar Degeneration and Related Disorders (Guest Editor: Barbara Borroni)]
Current Alzheimer Research Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Editors Note
Current Molecular Medicine Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design Transforming Cytosolic Proteins into “Insoluble” and Membrane-toxic Forms Triggering Diseases/Aging by Genetic, Pathological or Environmental Factors
Protein & Peptide Letters Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Gastric Inhibitory Polypeptide and its Receptor are Expressed in the Central Nervous System and Support Neuronal Survival
Central Nervous System Agents in Medicinal Chemistry Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research